Overview

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

Status:
Completed

Trial end date:
2021-01-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with active proliferative lupus nephritis (LN).

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Antibodies, Monoclonal